GSK is making a deliberate choice not to compete in the GLP-1 weight-loss race. Instead, the company is building a cardiometabolic strategy around the complications of obesity rather than weight loss itself. The SiranBio deal is the clearest articulation of this approach. SA030 is a long-acting siRNA that silences ALK7, a receptor involved in fat storage and inflammation. In preclinical studies, ALK7 inhibition reduced abdominal visceral fat while preserving lean muscle mass—a combination that GLP-1s have struggled to achieve. SiranBio described SA030 as having “a complementary and distinct mechanism to GLP-1 agonists, supporting future combination approaches.” GSK will pay up to $1.005 billion in milestones plus royalties. CEO Luke Miels has said the GLP-1 space is going to be “very crowded” and that GSK’s focus is “more on the downstream effects of obesity rather than addressing the actual obesity itself.” The implication is that SA030 could be used alongside Wegovy, Foundayo, or any GLP-1 to address the cardiometabolic risk that persists even after weight loss. Meanwhile, Bayer broke a five-year pharma M&A drought with its $300 million Perfuse acquisition. Viridian’s elegrobart hit Phase 3 in thyroid eye disease with plans to file for approval in Q1 2027. And SCOTUS mifepristone briefs are due today.
Top Story: GSK Licenses Fat-Targeting siRNA from SiranBio for Up to $1B
What Happened: GSK entered an exclusive licensing agreement with Suzhou-based SiranBio on May 6 for worldwide rights (excluding Greater China) to SA030, a long-acting siRNA targeting activin receptor-like kinase 7 (ALK7). GSK will pay an undisclosed upfront plus up to $1.005 billion in development, regulatory, and commercial milestones, plus tiered royalties on net sales. SiranBio will complete Phase 1 studies, after which GSK assumes responsibility for further development, regulatory filings, and commercialization.
The Science: Targeting Fat Cells Directly
ALK7 is a receptor involved in adipocyte (fat cell) biology. SA030 uses adipocyte-directed delivery to silence ALK7 specifically in fat tissue. In preclinical models, ALK7 inhibition produced a distinctive pharmacological profile:
Reduced abdominal visceral fat while preserving lean muscle mass. This is the combination that makes ALK7 inhibition fundamentally different from GLP-1 therapy. GLP-1s drive weight loss primarily through appetite suppression and delayed gastric emptying, but a meaningful portion of the weight patients lose on GLP-1 therapy is lean mass, including muscle. For older patients, patients with sarcopenia risk, or patients whose primary health concern is metabolic risk rather than total body weight, the loss of muscle alongside fat is a significant clinical limitation.
Improved insulin sensitivity and blood lipid profiles. The metabolic improvements in preclinical models went beyond fat reduction to include favorable changes in glucose handling and circulating lipids—markers that are directly tied to cardiovascular and metabolic disease risk.
Reduced fat cell-driven inflammation. Visceral fat is not inert tissue. It is an active endocrine organ that produces inflammatory cytokines contributing to cardiovascular disease, insulin resistance, and metabolic syndrome. Silencing ALK7 in adipocytes reduced this inflammatory output in preclinical studies.
SiranBio described a “long-acting profile” supporting low-frequency dosing, which suggests SA030 could be administered as infrequently as once monthly or less—a convenience feature that would make it practical as an add-on therapy to daily or weekly GLP-1 regimens.
The Strategic Logic: Complementing GLP-1s Rather Than Competing
GSK CEO Luke Miels told reporters in February: “I think it’s going to be very crowded,” referring to the GLP-1 space. “Our focus is more on the downstream effects of obesity rather than addressing the actual obesity itself.”
SA030 fits that strategy precisely. The drug is positioned as complementary to GLP-1s rather than competitive with them. A patient taking Wegovy, Foundayo, or any GLP-1 for weight loss could add SA030 to address the composition of the weight being lost—ensuring that the reduction comes from visceral fat rather than a mix of fat and muscle. The combination would target both appetite (GLP-1) and fat cell biology (ALK7) through independent mechanisms.
SiranBio stated SA030 has “a complementary and distinct mechanism to GLP-1 agonists, supporting future combination approaches.” That language explicitly positions the drug for co-administration rather than standalone use.
The Competitive Landscape in ALK7
GSK is not the only company pursuing this target. Arrowhead Pharmaceuticals already has Phase 1/2a data for ARO-ALK7, an RNAi therapy targeting the same receptor, in combination with Lilly’s Zepbound. Arrowhead is more advanced clinically than SA030, which is still in Phase 1.
The $1 billion GSK deal validates ALK7 as a target that major pharma considers commercially significant. If both programs succeed in demonstrating the preclinical profile in human patients—visceral fat reduction with lean mass preservation—ALK7 inhibition could become a validated therapeutic category adjacent to GLP-1 therapy rather than a speculative bet. The combination of GLP-1 plus ALK7 inhibitor could eventually become a standard treatment approach for patients who want both weight loss and favorable body composition.
This is also the latest example of a Western pharma company licensing assets from Chinese biotechs, following the pattern established by Lilly (Hengrui/Kailera), AbbVie (Haisco Nav1.8 pain inhibitors), and others throughout 2026.
Our Pro brief analyzes why ALK7 could become the next major target in obesity-adjacent medicine, how GSK’s “downstream” strategy compares to competing directly in GLP-1, and how the Arrowhead Phase 1/2a data positions against SA030. [Details below.]
What to Watch
SiranBio’s Phase 1 completion is the immediate milestone. Once Phase 1 data are available, GSK takes over development and will make go/no-go decisions on Phase 2 and registrational development. The key question: does ALK7 inhibition produce the same selective visceral fat reduction and lean mass preservation in humans that it produces in preclinical models? If it does, the combination thesis becomes clinically validated and the commercial opportunity expands dramatically—because every patient on a GLP-1 becomes a potential candidate for add-on ALK7 therapy.
If the human data do not replicate the preclinical profile—either because the fat reduction is insufficient, because lean mass is not preserved as cleanly, or because safety signals emerge—the $1 billion milestone structure limits GSK’s downside. The deal is structured so that the largest payments are contingent on clinical and commercial success, protecting GSK from overpaying for a mechanism that does not translate.
The Arrowhead Phase 1/2a data for ARO-ALK7 in combination with Zepbound will also be closely watched. Arrowhead’s more advanced clinical position means it could provide the first human validation of the ALK7 thesis before SA030 completes Phase 1, effectively de-risking GSK’s investment through a competitor’s data.
Bayer Acquires Perfuse for $300M in First Pharma Deal Since 2021
What Happened: Bayer acquired Perfuse Therapeutics for $300 million upfront, marking the company’s first pharmaceutical acquisition since 2021. Perfuse is developing an eye implant for sustained drug delivery in glaucoma and diabetic retinopathy.
Why This Matters
The five-year M&A drought at Bayer reflects the company’s complex strategic position: a diversified conglomerate spanning pharma, crop science, and consumer health that has faced litigation costs from its Monsanto acquisition and corporate restructuring pressure. The Perfuse deal signals renewed dealmaking appetite, even if the $300 million scale is modest compared to the multi-billion-dollar transactions dominating pharma headlines.
The asset addresses a genuine unmet need. Glaucoma management depends on daily eye drops that patients frequently use incorrectly or inconsistently. Patient compliance with drop regimens is the primary barrier to effective glaucoma treatment, with studies consistently showing that a large percentage of patients miss doses or apply drops improperly. A sustained-release implant that delivers medication continuously without daily patient action would fundamentally change the treatment paradigm.
Diabetic retinopathy—a complication of diabetes that damages blood vessels in the retina—is another condition where sustained drug delivery could improve outcomes over the current standard of periodic intravitreal injections. Bayer already has a presence in ophthalmology through its anti-VEGF franchise, making Perfuse a natural strategic fit.
Clinical Updates
Viridian’s Elegrobart Hits Phase 3 in Thyroid Eye Disease
What Happened: Viridian Therapeutics reported positive Phase 3 results for elegrobart in thyroid eye disease (TED). The drug normalized the degree of eye protrusion (proptosis) and improved double vision in treated patients. Viridian plans to file for approval in Q1 2027.
The Competitive Context
Elegrobart would compete with Amgen’s Tepezza (teprotumumab), the only FDA-approved TED treatment, which requires eight infusions over 21 weeks. Tepezza has built a substantial franchise since its approval. If elegrobart demonstrates a more convenient dosing profile—fewer infusions, a subcutaneous option, or a shorter treatment course—it could capture meaningful market share from Tepezza’s entrenched position.
The TED market is expected to grow as diagnosis rates improve. Many patients with thyroid eye disease are not diagnosed until the condition has progressed significantly, and growing awareness among endocrinologists and ophthalmologists is expanding the diagnosed population. A second approved treatment option would further accelerate diagnosis and treatment initiation by giving physicians more flexibility in how they manage the disease.
This is also relevant to the Immunovant story covered earlier this year. Immunovant’s batoclimab failed in TED (both Phase 3 studies missed their primary endpoint in April), while the company pivoted to IMVT-1402 in Graves’ disease. Viridian’s success with a different mechanism demonstrates that TED is a treatable condition—the batoclimab failure was mechanism-specific rather than disease-specific. The TED market can support a second entrant if the drug demonstrates meaningful clinical benefit, and elegrobart’s proptosis normalization data suggest it does. Viridian’s Q1 2027 filing timeline means an approval could come in late 2027 or early 2028, creating a competitive dynamic that Amgen’s Tepezza team will need to prepare for.
SCOTUS Mifepristone: Briefs Due Today
Briefs from Louisiana and the FDA are due today (May 7) in the mifepristone case. Justice Alito’s administrative stay, which restored telehealth and mail access to mifepristone after the 5th Circuit reinstated in-person dispensing requirements, expires May 11. The full Court will then decide whether to extend the stay, let the 5th Circuit ruling take effect, or take the case on the merits.
The pharmaceutical industry implications remain significant. The core question—whether federal courts can override FDA scientific determinations on how approved drugs reach patients—affects every company with products distributed through telehealth, modified REMS programs, or expanded dispensing provisions.
Strategic Themes
1. GSK’s “Downstream” Strategy Could Be the Smartest Move in the Obesity Market
Every major pharma company has entered or attempted to enter the GLP-1 weight-loss market. The result, as Miels noted, is a crowded competitive landscape where differentiation is increasingly difficult. GSK chose to address what happens after weight loss—the cardiometabolic complications that persist in most obese patients regardless of whether they take a GLP-1. If SA030 works, GSK would own a category where every GLP-1 patient is a potential customer. That is a fundamentally different commercial proposition than trying to be the fifth or sixth GLP-1 entrant fighting for share in a $200-billion-plus market.
2. The Lean Mass Preservation Question Could Reshape How Physicians Prescribe GLP-1s
The clinical concern that GLP-1 patients lose muscle along with fat is real and growing. As the GLP-1 patient population expands to include older adults, patients with lower baseline muscle mass, and long-term users who have been on therapy for years, the lean mass question becomes more urgent. ALK7 inhibitors that preserve muscle while targeting visceral fat could become standard add-on therapy—not because GLP-1s do not work, but because GLP-1s alone do not address the body composition dimension of metabolic health. If combination therapy becomes the norm, the ALK7 market could be nearly as large as the GLP-1 market itself.
3. Bayer’s Return to Pharma M&A Signals the Buyer Pool Is Still Widening
Five years without a pharma acquisition made Bayer an outlier among large diversified healthcare companies. The Perfuse deal, while modest in scale, signals that even companies with complex corporate situations and balance sheet constraints are beginning to participate in the M&A cycle. Combined with Teva ($900 million Emalex), UCB ($1.15 billion Neurona), and Chiesi ($1.9 billion KalVista), the expanding buyer pool suggests the M&A wave has room to broaden further beyond the mega-cap companies that have dominated deal flow to date.
4. Viridian’s Success in TED Validates the Market That Immunovant’s Batoclimab Could Not Crack
Viridian and Immunovant both targeted thyroid eye disease in Phase 3 trials. Immunovant’s batoclimab missed on both studies. Viridian’s elegrobart succeeded. The contrast illustrates that TED is not an untreatable condition—the failure was mechanism-specific, not disease-specific. Viridian’s success and its Q1 2027 filing timeline create a competitive threat to Amgen’s Tepezza franchise and validate the TED market as commercially viable for a second entrant.
Frequently Asked Questions
What is SA030, and why is GSK paying up to $1B?
SA030 is a long-acting siRNA that silences ALK7, a receptor involved in fat cell biology. In preclinical models, it reduced abdominal visceral fat while preserving lean muscle mass and improved insulin sensitivity and blood lipid profiles. GSK is paying up to $1.005 billion in milestones plus royalties because the drug could complement every GLP-1 on the market rather than competing with them.
How is SA030 different from GLP-1 drugs?
GLP-1s drive weight loss primarily through appetite suppression and delayed gastric emptying. SA030 targets fat cell biology directly through ALK7 inhibition, reducing visceral fat while preserving lean mass. The mechanisms are complementary rather than competitive, supporting combination use where the GLP-1 drives total weight loss and SA030 ensures the weight lost is fat, not muscle.
Who else is developing ALK7 inhibitors?
Arrowhead Pharmaceuticals has ARO-ALK7 in Phase 1/2a in combination with Lilly’s Zepbound. Arrowhead is more clinically advanced than SA030, which is still in Phase 1 under SiranBio. The $1 billion GSK deal validates ALK7 as a target that major pharma considers commercially significant.
What did Bayer acquire?
Perfuse Therapeutics for $300 million upfront. Perfuse is developing an eye implant for sustained drug delivery in glaucoma and diabetic retinopathy. This is Bayer’s first pharmaceutical acquisition since 2021, signaling renewed deal appetite.
What were Viridian’s Phase 3 results?
Elegrobart normalized eye protrusion (proptosis) and improved double vision in thyroid eye disease patients. Viridian plans to file for approval in Q1 2027. The drug would compete with Amgen’s Tepezza, the only approved TED treatment.
What is the SCOTUS mifepristone timeline?
Briefs due today (May 7). Justice Alito’s administrative stay expires May 11. The full Court will then decide whether to extend the stay, let the 5th Circuit ruling take effect, or take the case on the merits.
Why does GSK say it is not competing with GLP-1s?
CEO Luke Miels said the GLP-1 space is going to be “very crowded” and that GSK’s focus is on “the downstream effects of obesity rather than addressing the actual obesity itself.” SA030 is designed to complement GLP-1 therapy by addressing the body composition and cardiometabolic risk dimensions that GLP-1s alone do not fully resolve.
How does this deal fit the China licensing trend?
SA030 is licensed from Suzhou-based SiranBio, making it the latest Western pharma deal with a Chinese biotech in 2026. Similar transactions include AbbVie/Haisco (Nav1.8 pain inhibitors) and the Kailera IPO (assets from Jiangsu Hengrui).
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
ALK7: The Next Obesity-Adjacent Target. We analyze why GSK and Arrowhead are betting on fat cell biology rather than appetite suppression, how the preclinical lean mass preservation data positions ALK7 inhibitors as GLP-1 add-ons rather than competitors, and what the Arrowhead Phase 1/2a data show about the target’s human translatability.
GSK’s Downstream Strategy. We map GSK’s cardiometabolic portfolio—SA030 (ALK7, fat reduction), FGF21 analog (MASH), and the broader complications-of-obesity thesis—against the crowded GLP-1 landscape and model the commercial opportunity for a complementary mechanism that every GLP-1 patient is a candidate for.
Viridian vs. Tepezza: The TED Competitive Showdown. We compare elegrobart’s Phase 3 profile against Tepezza’s established franchise, assess what dosing convenience improvements could drive switching, and model the market share implications of a second approved TED treatment.
Plus: SCOTUS mifepristone timeline, Bayer ophthalmology strategy, Fierce Biotech Week preview, ASCO 23-day countdown, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
